Skip to main content
Wockhardt Ltd logo

Wockhardt Ltd — Investor Relations & Filings

Ticker · WOCKPHARMA ISIN · INE049B01025 LEI · 3358001OC2OX7OZAHZ33 BSE.NS Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country IN India
Listing BSE.NS WOCKPHARMA

About Wockhardt Ltd

https://www.wockhardt.com/

Wockhardt Ltd is a research-driven global organization focused on the development and manufacturing of formulations, biopharmaceuticals, and active pharmaceutical ingredients (APIs). The company maintains a specialized focus on drug discovery, particularly in the field of anti-infectives and New Chemical Entities (NCEs) aimed at addressing antimicrobial resistance. Its therapeutic portfolio encompasses diverse areas such as diabetes, nephrology, cardiology, and respiratory health. With a strong emphasis on research and development, the company operates multiple manufacturing facilities that comply with international regulatory standards. Wockhardt provides medical solutions across various international markets, utilizing its expertise in complex chemistry and biotechnology to address unmet clinical needs.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Annual Secretarial Compliance Report for the year ended 31st March, 2026
Regulatory Filings Classification · 90% confidence The document is titled “Annual Secretarial Compliance Report for the Year Ended 31st March, 2026,” prepared and signed by the Practicing Company Secretary under SEBI LODR Regulation 24A. It is an attestation/certification of statutory compliance rather than the actual financial statements or governance report itself. Per the Certification Rule, officer certifications and compliance attestations should be classified as a regulatory filing. Therefore, this falls under the Regulatory Filings category (RNS).
2026-05-28 English
Press Release
Regulatory Filings Classification · 91% confidence The document is a press release submitted under Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements to BSE and NSE. It announces marketing authorization for a drug, contains no financial statements or earnings data, and serves as a stock exchange disclosure. This is a general regulatory announcement that does not fit any other specific category, so it should be classified as a Regulatory Filing (RNS).
2026-05-28 English
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Indian drug regulator grants marketing authorization to Wockhardt''s breakthrough antibiotic , ZAYNICH ....
Regulatory Filings Classification · 95% confidence The document is a letter under Regulation 30 of SEBI LODR submitting a press release to the stock exchanges. It does not contain financial statements, management discussion, or formal report content; rather, it is a regulatory announcement of company news. It is a typical example of a general regulatory filing (press release) under RNS.
2026-05-28 English
ICRA Limited has upgraded the Credit Rating as given below: Long Term- Fund Based- Term Loan- Present Rating- A- (Stable); Previous Rating- BBB (Positive) Long Term/ Short Term- Fund ....
Regulatory Filings Classification · 85% confidence The document is a formal stock exchange announcement informing investors and regulators that ICRA Limited has upgraded the company’s credit ratings. It does not contain financial statements or detailed financial report content, nor is it announcing dividends, m&a, board changes, or share issuances. It is a routine regulatory announcement that doesn’t fit any specialized category, so it falls under the Residual Regulatory Filings category (RNS).
2026-05-21 English
Credit Rating
Regulatory Filings Classification · 85% confidence The document is a stock exchange filing notifying investors of a credit rating upgrade by ICRA. It is not an actual financial report (e.g., annual or interim report), nor a dividend notice or board change. It is a general regulatory announcement to exchanges, fitting the ‘Regulatory Filings’ category (RNS).
2026-05-21 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended March 31, 2026' and relates to the utilization of proceeds from a Qualified Institutional Placement (QIP). It is issued by Crisil Ratings Limited as the Monitoring Agency and includes detailed information on the use of funds, compliance with SEBI regulations, and certifications by independent accountants. The content is a formal report on the monitoring of capital raised through a financing activity, specifically the QIP proceeds utilization. This fits the category of a Capital/Financing Update (CAP), as it provides updates on the company's fundraising and capital utilization. The document is substantive and not merely an announcement or certification, and it is not an annual or interim financial report, nor an audit report or other category. Therefore, the appropriate classification is CAP with high confidence.
2026-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.